177Lu-PSMA-617 (177Lu-Vipivotide tetratexan) is a 177Lu labeled peptide developed for the therapy of metastasized castrate resistant prostate cancer (mCRPC). This molecule is an IP protected molecule back-up of PSMA-11.
PSMA-617 is primarily developed as a therapeutic agent labeled with 177Lu.
Data published in December 2016 based on 145 patients with mCRPC who received treatment with 177Lu-PSMA-617 for radioligand therapy and treated in 12 therapy centers show that 45% of patients had a positive response to treatment after receiving all treatment cycles, and 40% responded after one cycle.
Obtained US FDA marketing authorization in March 2022 (under the name of PluvictoTM ).
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.